HUTCHMED Highlights Data at ESMO and ASH
HUTCHMED to present clinical data from multiple drug studies at ESMO Asia Congress and ASH Annual Meeting.
Select text to share a quote on X · sign in to keep highlights & notes in your HCM notes
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ESMO Asia Congress and the 2025 ASH Annual Meeting
Hong Kong, Shanghai & Florham Park, NJ - Thursday, November 27, 2025: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology ("ESMO") Asia Congress 2025, taking place on December 5-7, 2025 in Singapore, and the American Society of Hematology ("ASH") Annual Meeting taking place on December 6-9, 2025 in Orlando, USA.
Results from a first-in-human study of the anti-CD47 monoclonal antibody HMPL-A83 in advanced solid tumors, as well as from the phase II part of the FRUSICA-2 registration study of the fruquintinib and sintilimab combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma, will be presented at the ESMO Asia Congress 2025. Results from the phase II part of the phase II/III study of surufatinib in combination with camrelizumab and chemotherapy as a first-line treatment for metastatic pancreatic cancer will also be reported. Details of the presentations are as follows:
| Abstract title | Presenter / Lead author | Presentation details | |
|---|---|---|---|
| ESMO Asia Congress 2025 - SPONSORED STUDIES | |||
| A first-in-human (FIH), dose escalation study of HMPL-A83 (A83), an anti-CD47 monoclonal antibody (mAb) in patients (pts) with advanced solid tumors | Ye Guo (Shanghai, China) | 162MO | Mini Oral session: Developmental therapeutics and precision medicine Sunday, December 7, 2025 11:40 - 11:45 SGT Hall 407 |
| Fruquintinib monotherapy as second-line (2L) treatment in locally advanced or metastatic renal cell carcinoma (RCC): results from phase 2 part of FRUSICA-2 | Shanshan Wang (Shanghai, China) | 540O | Proffered Paper session: Genitourinary tumours Friday, December 5, 2025 14:55 - 15:05 SGT Hall 402 |
| Surufatinib (S) in combination with camrelizumab (C), nab-paclitaxel and gemcitabine (AG) as the first-line treatment in metastatic pancreatic cancer: results from phase 2 part of a randomized, open-label, active-controlled, phase 2/3 study | Shukui Qin (Nanjing, China) | 375P | Poster Display: Gastrointestinal tumours, non‑colorectal |
| Osimertinib (osi) + savolitinib (savo) in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) with MET overexpression and/or amplification (OverExp/Amp) following progressive disease (PD) on osi: SAVANNAH Asian subset | Se-Hoon Lee (Seoul, Korea) | 982P | Poster Display: Thoracic tumours, metastatic |
| Patient-relevant Outcomes (PROs) from SACHI: a Phase 3 Trial of Savolitinib (Savo) plus Osimertinib (Osi) versus Chemotherapy (Chemo) in EGFR-mutant (EGFRm) and MET-amplified (METamp) Advanced NSCLC after Progression on EGFR-TKIs | Yongfeng Yu (Shanghai, China) | 984P | Poster Display: Thoracic tumours, metastatic |
| Analysis of MET Amplification (METamp) with FISH and NGS Method in SACHI Trial | Longhua Sun (Nanchang, China) | 988P | Poster Display: Thoracic tumours, metastatic |
| Progression pattern in patients (pts) with EGFR-mutant (EGFRm), MET-amplified (METamp) advanced NSCLC treated with savolitinib (savo) plus osimertinib (osi) | Haiyan Yang (Changsha, China) | 1002P | Poster Display: Thoracic tumours, metastatic |
| MET testing and treatment (tx) sequencing after progression of disease (PD) on first-line (1L) osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification (OverExp/Amp): Final analysis of a global real-world (rw) study | Julia Rotow (Boston, US) | 1005P | Poster Display: Thoracic tumours, metastatic |
| ESMO Asia Congress 2025 - INVESTIGATOR-INITIATED STUDIES | |||
| Fruquintinib Combined with TAS-102 with or without SBRT as Third- or Later-Line Treatment in Metastatic Colorectal Cancer: Preliminary Results from a Prospective Phase II Trial | Chen Zhang/ Yi Wang (Ningbo, China) | 205P | Poster Display: Gastrointestinal tumours, colorectal |
| Efficacy and safety of fruquintinib combined with PD-1 inhibitor and chidamide in MSS mCRC: a comparison with real-world bevacizumab plus anti-pd-1 and chidamide arm | Guanghai Dai/ Miaomiao Gou (Beijing, China) | 245eP | Poster Display: Gastrointestinal tumours, colorectal |
| The Efficacy and Safety of Fruquintinib (F) Plus FOLFIRI as Second-line (2L) Treatment in Bevacizumab (Bev)-pretreated RAS-mutated (RAS‑m) Metastatic Colorectal Cancer (mCRC) | Zhenyang Liu/ Xiaolin Yang (Changsha, China) | 250eP | Poster Display: Gastrointestinal tumours, colorectal |
| Real-world Observational Study of Fruquintinib in Combination with Irinotecan and Capecitabine as Second-line Treatment in Patients with Advanced Colorectal Cancer | Xiujuan Qu/ Lin Xu (Shenyang, China) | 255eP | Poster Display: Gastrointestinal tumours, colorectal |
| Matching-Adjusted Indirect Comparison of Surufatinib versus High-Dose Octreotide LAR in Advanced Extrapancreatic Neuroendocrine Tumors | Jianming Xu (Beijing, China) | 214P | Poster Display: Gastrointestinal tumours, colorectal |
| Efficacy and safety of surufatinib in combination with CAPTEM as conversion therapy in patients with unresectable pancreatic neuroendocrine tumors (pNETs): Data updates from a prospective, open-label study | Xubao Liu/ Ziyao Wang (Chengdu, China) | 400P | Poster Display: Gastrointestinal tumours, non ‑ colorectal |
Final analysis of long-term results of sovleplenib's ESLIM-01 China Phase III study in in adult patients with chronic primary immune thrombocytopenia will be presented at the 2025 ASH Annual Meeting. Details of the presentation is as follows:
| Abstract title | Presenter / Lead author | Presentation details | |
|---|---|---|---|
| 2025 ASH Annual Meeting - SPONSORED STUDIES | |||
| Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia | Renchi Yang (Tianjin, China) | 843 | Oral Abstract Session Monday, December 8, 2025 15:15 - 15:30 EST Room OCCC - W304EFGH |
About Fruquintinib
Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors ("VEGFR") -1, ‑2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE®. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA®.
About HMPL-A83
HMPL-A83 is an investigational IgG4-type humanized anti-CD47 monoclonal antibody that exhibits high affinity for CD47. HMPL-A83 blocks CD47 binding to Signal regulatory protein (SIRP) α and disrupts the "do not eat me" signal that cancer cells use to shield themselves from the immune system. HUTCHMED currently retains all rights to HMPL-A83 worldwide.
About Savolitinib
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS®.
About Surufatinib
About Sovleplenib
Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting the spleen tyrosine kinase, also known as Syk. Syk is a major component in B-cell receptor and Fc receptor signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders. HUTCHMED currently retains all rights to sovleplenib worldwide.
Medical Information
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.